Ahrens FA and Aronson AL: Toxicity of calcium ethylenediaminetetraacetate in dogs. Fed Proc Fedn Am Soc Exp Biol 27:1401, 1968.
Ahrens FA, Aronson AL: A comparative study of the toxic effects of calcium and chromium chelates of ethylendiaminetatraacetate in the dog. Toxicol Appl Pharmacol 1971;18:10-25.
Alfthan G, Pikkarainen J, Huttunen JK, Puska P: Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982;2(8291):175-79.
Altman J, Wakim KG and Winkelmann RK: Effects of edathamil disodium on the kidney. J Invest Derm 38:215-218, 1962.
American Board of Chelation Therapy. Constitution and By-Laws, April 1983. American Board of Chelation Therapy, 1312 N.W. Twelfth Street, Moore, Oklahoma 73170.
Ames BN: Dietary carcinogens and anticarcinogens. Science 1983;221:1256-64.
Angle CR and McIntire MS: Lead poisoning during pregnancy. Fetal tolerance of calcium disodium edetate . Am J Dis Child 108:436, 1964.
Aranov DM: First experience with the treatment of atherosclerosis patients with calcinosis of the arteries with trilon-B (disodium salt of EDTA). Klin Med (Russ, Moscow) 1963;41:19-23.
Aronson AL and Ahrens FA: The mechanism of renal transport and excretion of ethylenediaminetetraacetate with interspecies comparison. Toxic Appl Pharmac 18:1, 1971.
Aronson AL and Hammond PB: Effect of two chelating agents on the distribution and excretion of lead. J Pharmacol Exp Ther 146:241-251, 1964.
Aronson AL, Hammond PB and Strafuss AC: Studies with calcium ethylenediaminetetraacetate in calves; toxicity and use in bovine lead poisoning. Toxicol Appl Pharmacol 12:337-349, 1968.
Athersclerosis and auto-oxidation of cholesterol. Lancet 1980;ii:964-65.
Babior BM: Oxygen-dependent microbial killing by phagocytes. N Engl J Med 1978;298:659-68.
Batchelor TM, McCall M and Mosher RM: Potassium dieresis induced by edathamil disodium. JAMA 187:305, 1964.
Bates GW, Billups C and Saltman P: The kinetics and mechanism of iron (III) exchange between chelates and transferrin. II. The presentation and removal with ethylenediaminetetraacetate. J Biol Chem 242:2816, 1967.
Batuman V, Landy E, Maesaka JK, Wedeen RP: Contribution of lead to hypertension with renal impairment. N Engl J Med 1983;5(2):871-879.
Bauer RO, Rullo FR, Spooner C and Woodman E: Acute and subacute toxicity of ethylene diamine tetraacetic (EDTA) salts. Fed Proceed 2:321, 1952.
Bechtel JT, White JE and Estes EH Jr: The electrocardiographic effects of hypocalcemia induced in normal subjects with edathamil disodium. Circulation 13:837, 1956.
Benditt EP: The origin of atherosclerosis. Scientific American Feb 1977, pp 74-85.
Berkman N, Michaeli Y, Or R and Eldor A: EDTA dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 36:195, 1991.
Bessman SP, Ried H and Rubin M: Treatment of lead encephalopathy with calcium disodium versenate. Ann Med Soc DC 21:312, 1952.
Birk RE and Rupe CE: Systemic sclerosis. Fourteen cases treated with chelation (disodium EDTA) and/or pyridoxine, with comments on the possible role of altered tryptophan metabolism in pathogenesis. Henry Ford Hosp Med Bull 10:523, 1962.
Birk RE, Rupe CE: The treatment of systemic sclerosis with EDTA, pyridoxine and reserpine. Henry Ford Hospital Medical Bulletin 1966 June;14:109-39.
Bjorksten J: Possibilities and limitations of chelation as a means for life extension. Rejuvenation 1980;8:67- 72.
Bjorksten J: The cross-linkage theory of aging as a predictive indicator. Rejuvenation 1980;8:59-66.
Black HS, Chan JT: Experimental ultraviolet light-carcinogenesis. Photochem Photobiol 1977;26:183-89.
Blake DR, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge JMC: Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis 1983;99:450-54.
Bliat RK, et al.: Trace elements in hair and environmental exposurel. Sci Total Environ 1982;22(2);169-78.
Blumer W and Cranton EM: Ninety percent reduction in cancer mortality after chelation therapy with EDTA. J Adv Med 2:183 1989.
Blumer W, Reich T: Leaded gasoline-a cause of cancer. Environmental International 1980;3:465-71.
Bolick LE and Blankenhor, DH: A quantitative study of coronary arterial calcification. Am J Path 39:511, 1961.
Boyle AJ, Casper JJ, McCormick H, et al.: Studies in human and induced atherosclerosis employing EDTA. (Swiss, Basel) Bull Schweiz Akad Med Wiss 1957;13:408.
Boyle AJ, Clarke NE, Mosher RE, McCann DS: Chelation therapy in circulatory and sclerosing diseases. Fed Proc 1961;20(3) (Part II) (suppl 10):243-57.
Boyle AJ, Jasper JJ, McCormick H, et al: Studies in human and induced atherosclerosis employing - (EDTA). Bull Swiss Acad Med Sci 13:408, 1957.
Boyle AJ, Mosher RE, McCann DS: Some in vivo effects of chelation-I: Rheumatoid arthritis. J Chronic Dis 1963; 16:325-28.
Brecher A: Bye-Bye Bypass: The Truth About Chelation Therapy. Troup, Texas, Health Savers Press, 1989.
Brien TG and Fay JA: 51Cr-EDTA biological half life as an index of renal function. (Letters) J Nucl Med 13:339, 1972.
Brucknerova 0, Tulacek J: Chelates in the treatment of occlusive atherosclerosis. (Czechoslovakian, Praha) Vnitr Lek 1972;12:137-39.
Brucknerova O and Malinovska V: First clinical experience with combined treatment with chelation III and glucagon in ischemic disease of the lower extremities. Cas Lek Cas 119:814, 1980.
Brucknerova O, Tulacek J and Krojzl O: Chelates in the treatment of obliterating arteriopathies. Vnitrni Lek 14:841, 1968.
Brugsch HG: Fatal nephropathy during edathamil therapy in lead poisoning. AMA Arch Indust Health 20:285, 1959.
Butterfield DJ: McGraw CP: Free radical pathology. Stroke 1978;9(5):443-45.
Calcium disodium edetate and disodium edetate. Drugs for human use; drug efficacy study implementation. Department of Health, Education, and Welfare. Food and Drug Administration. Federal Registrar 35 F.R. 437, 1970.
Capel ID, Spencer EP, Levitt HN, Daivies AE: Assessment of zinc status by the zinc tolerance test in various groups of patients. Clin Biochem 1982;15(2):257-60.
Carpenter DG: Correction of biological aging. Rejuvenation 1980;8:31-49.
Casdorph HR, Farr CH; EDTA chelation therapy III: Treatment of peripheral arterial occlusion, an alternative to amputation. J Holistic Med 1983;5(l):3-15.
Casdorph HR: Chelation therapy: a reappraisal. N Z Med J 66, 1983.
Casdorph HR: EDTA chelation therapy - efficacy in arteriosclerotic heart disease. J Holistic Med 3:53, 1981.
Casdorph HR: EDTA chelation therapy II, efficacy in brain disorders. J Holistic Med 1981;3(2):101-17.
Cashion WR Jr: What about chelation? Texas Medicine 80:6, 1984.
Castellino N and Aloj S: Effects of calcium sodium ethylenediaminetetra-acetate on the kinetics of the distribution and excretion of lead in the rat. Brit J Indust Med 22:172, 1965.
Catsch A: Radioactive metal mobilization. Fed Proc 20 (Suppl 10):206, 1961.
Chaitlow L: Chelation Therapy: The Revolutionary Alternative to Heart Surgery. San Francisco, Thorsons SF, 1991.
Chantler C and Barratt TM: Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 47:613, 1972.
Chantler C, Garnett ES, Parsons V and Veall N: Glomerular filtration rate measurement in man by the single injection method using 51Cr-EDTA. Clin Sci 37:169, 1969.
Chappell LT and Stahl JP: The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 6:139, 1993.
Chappell LT, Miranda R, Rubin M, Carter JP and Trowbridge J: Chelation therapy (Letter). Circulation 92:1350, 1995.
Chappell LT: Chelation therapy, smoking and health care costs (Letter). J Adv Med 7:107, 1994.
Chappell LT: EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Alternative Therapies Health Med 1:53, 1995.
Chelation therapy - An informal summary. Department of Health & Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland. June 1992.
Chelation therapy (Diagnostic and therapeutic technology assessment). JAMA 250:672, 1983.
Chelation Therapy Clinic: Chelation Therapy - The Treatment of Choice for Relief From and Prevention of, Cardiovascular and Age-Related Diseases. Auckland, New Zealand, The Chelation Therapy Clinic, 1987.
Chelation therapy. Report of the Council on Scientific Affairs. Report F (I-84). AMA House of Delegates. 1984.
Chelation therapy. Resolution: 66 (I-84). AMA House of Delegates. 1984.
Chelation therapy: a second look. The Harvard Medical School Health Letter IX:1, 1984.
Chen IW, Park HM, King LR, Bahr GK and Goldsmith RE: Radioimmunoassay of parathyroid hormone: peripheral plasma immunoreactive parathyroid hormone response to ethylenediaminetetraacetate. J Nucl Med 15:763, 1974.
Chisolm JJ Jr: Chelation therapy in children with subclinical plumbism. Pediatrics 53:441, 1974.
Chisolm JJ Jr: The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediat 73:1, 1968.
Cimino JA, Demopoulos HB: Introduction: Determinants of cancer relevant to prevention, in the war on cancer. Journal of Environmental Pathology and Toxicology 1980;3:1-10
Clark NE Sr, Atherosclerosis, occlusive vascular disease and EDTA. (Ed) Am J Cardiol 6:233, 1960.
Clarke NE Sr, Clarke NE Jr, Mosher RE: Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA) Am J Med Sci, 239:732, 1960.
Clarke NE, Clarke CN, Mosher RE: The " in vivo " dissolution of metastatic calcium: An approach to atherosclerosis. Am J Med Sci 1955;229:142-49.
Clarke NE, Clarke CN, Mosher RE: Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 232:654, 1956.
Clarke NE, Sr: Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol 1960;6:233-36.
Cohen S, Weissler AM and Schoenfeld CD: Antagonism of the contractile effect of digitalis by EDTA in the normal human ventricle. Am Heart J 69:502, 1965.
Collipp PJ, Kuo B, Castro-Magana M, Chen SY, Salvatore S: Hair zinc levels in infants. Clin Pediatr 1983;22(7):512-13.
Conti CR: Chelation therapy for atherosclerosis: one man's view. Clin Cardiol 18:545, 1995.
Cook JD, Finch CA, Smith NJ: Evaluation of the iron status of a population. Blood 1976;48:449-55.
Coon MJ: Oxygen activation in the metabolism of lipids, drugs and carcinogens. Nutr Rev, 1978;36:319-28.
Coon MJ: Reconstitution of the cytochrome P-450-containing mixed-function oxidase system of liver microsomes. Methods Enzymol 1978;52:200-06.
Coon MK, van der Hoeven TA, Dahl SB, Haugen DA: Two forms of liver microsornal cytochrome P-450, P- 4501m2 and P-45OM4 (rabbit liver). Methods Enzymol 1978;52:109-17.
Couric JM: Chelation therapy overdone. FDA Consumer 16:28. 1982.
Cranton EM and Brecher A: Bypassing Bypass: The New Technique of Chelation Therapy. New York, Stein and Day, 1990.
Cranton EM and Frackelton JP: Current status of EDTA chelation therapy in occlusive arterial disease. J Holistic Med 1:24, 1982.
Cranton EM and Frackelton JP: Free radical pathology in age-associated diseases: treatment with EDTA chelation, nutrition and antioxidants. J Holistic Med 6:6, 1984.
Cranton EM and Frackelton JP: Negative Danish study of EDTA chelation biased (Letter). Townsend Letter Doctors. July, 604-605, 1992.
Cranton EM, Bland JS, Chatt A, Krakovitz R, Wright JV: Standardization and interpretation of human hair for elemental concentrations. J Holistic Med 1982;4:10-20.
Cranton EM, Frackelton JP: Current status of EDTA chelation therapy in occlusive arterial disease. J Holistic Med 1982;4:24-33.
Cranton EM: A textbook on EDTA chelation therapy. J Adv Med 2:1-416, 1989.
Cranton EM: Kidney effects of ethylene diamine tetraacetic acid (EDTA): A literature review. J Holistic Med 1982;4:152-157.
Cranton EM: Protocol of the American College of Advancement in Medicine for the safe and effective administration of EDTA chelation therapy. J Adv Med 2:269, 1989.
Cranton EM: The current status of EDTA chelation therapy. J Holistic Med 7:3, 1985.
Crapper-McLaughlin DR: Aluminum Toxicity in senile dementia: Implications for treatment. Read before the Fall Conference, American Academy of Medical Preventics, Las Vegas, Nevada, Nov 8, 1981. (Available on audio cassette from AAMP, 6151 West Century Blvd., *1114, Los Angeles, CA 90045.)
Craven PC and Morrelli HF: Chelation therapy. West J Med 122:277, 1975.
Crook WG: The coming revolution in medicine. J Tenn Med Assn 1983;76(3):145-49.
Crook WG: The Yeast Connection: A Medical Breakthrough. Jackson, TN, Professional Books, 1983 (P.O. Box 3494, Jackson, TN 38301). JOURNAL OF HOLISTIC MEDICINE
Curran CL: Metal chelating agents and hepatic cholesterol synthesis. Proc Soc Exper Biol & Med 88:101, 1955.
Darwish NM and Kratzer FH: Metabolism of ethylenediaminetetraacetic acid (EDTA) by chickens. J Nutr 86:187, 1965.
David 0, Hoffman SP, Sverd J, Clark J, Voeller K: Lead and hyperactivity, behavioral response to chelation: A pilot study. Am J Psychiatry 1976; 133:1155-58. 32
Davis FA, Becker FO, Michael JA and Sorensen E: Effect of intravenous sodium bicarbonate disodium EDTA and hyperventilation on visual and oculomotor signs in multiple sclerosis. J Neurol Neuro-surg Psychiat 33:723, 1970.
Davis H and Moe PJ: Favorable response of calcinosis universalis to edathamil disodium. Pediatriacs 24:780, 1959.
Davis PS and Deller DJ: Effect of orally administered chelating agents EDTA, DTPA and fructose on radioiron absorption in man. Aust Ann Med 16:70, 1967.
de Jesus-Greenberg D: Hyperbaric oxygen therapy. Critical Care Update 1981;8(2):8-20.
De La Torre JC, Johnson CM, Goode DJ, Mullan S: Pharmacologic treatment and evaluation of permanent experimental spinal cord trauma. Neurology 1975;25:508-14.
De La Torre JC, Kawanaga HM, Rowed DW, et al.: Dimethyl sulfoxide in central nervous system trauma. Ann NY Acad Sci 1975, 243:362-89.
De La Torre JC, Surgeon JW: Dexamethasone and DMSO in experimental transorbital cerebral infaretion. Stroke 1976;7:577-83.
Del Maestro RF: An approach to free radicals in medicine and biology. Acta Physiol Scand 1980;492(suppl):153-68.
DeLuca HF, Frost HM, Jae WSS, et al. (ads.): Osteoporosis: Recent Advances in Pathogenesis and Treatment. Baltimore, Univerisity Park Press, 1981.
Demopoulos HB, Flamm ES, Pietronigro DD, Seligman ML: The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand 1980;492(suppl):91-119.
Demopoulos HB, Flamm ES, Seligman ML, Jorgensen E, Ransohoff J: Antioxidant effects of barbiturates in model membranes undergoing free radical damage. Acta Neurol Scand 1977;56(suppl 64):152.
Demopoulos HB, Flamm ES, Seligman ML, Mitamura JA, RansohoffJ: Membranes perturbations in central nervous system injury: Theoretical basis for free radical damage and a review of the experimental data, in Popp AJ, Bourke LR, Nelson LR, Kimelbert HK (eds.): Neural Trauma. New York, Raven Press, 1979, 63-78.
Demopoulos HB, Flamm ES, Seligman ML, Pietronigro DD, Tomasula T, DeCrescito V: Further studies on free-radical pathology in the major central nervous system disorders: effect of very high doses of methylprednisolone on the functional outcome; morphology, and chemistry of experimental spinal cord impact injury. Can J Physiol Pharacol 1982;60(11):1415-24.
Demopoulos HB, Flamm ES, Seligman ML, Pietronigro DD: Oxygen free radicals in central nervous system ischemia and trauma, in Autor AP (ed.): Pathology of Oxygen. New York, Academic Press, 1982, 127-55.
Demopoulos HB, Flamm ES, Seligman ML, Ransohoff J: Molecular pathogenesis of spinal cord degeneration after traumatic injury, in Naftchi NE (ed.): Spinal Cord Injury. New York and London, Spectrum Productions, Inc. 1982, 45-64.
Demopoulos HB, Pietronigro DD, Flamm ES, Seligman ML: The possible role of free radical reactions in carcinogenesis. Journal of Environmental Pathology and Toxicology 1980;3:273-303.
Demopoulos HB, Pietronigro DD, Seligman ML: The development of secondary pathology with free radical reactions as a threshold mechanisms. Journal of the American College of Toxicology 1983;2(3):173-84.
Demopoulos HB: Control of free radicals in the biologic systems. Fed Proc 1973;32:1903-08.
Demopoulos HB: Molecular oxygen in health and disease. Read before the American Academy of Medical Preventics Tenth Annual Spring Conference, Loa Angeles, California May 21, 1983. (Available on three audio cassettes from Instatape, P.O. Box 1729, Monrovia, CA 91016.)
Demopoulos HB: The basis of free radical pathology. Fed Proc 1973;32:1859-61.
Deucher DP: EDTA chelation therapy: an antioxidant strategy. J Adv Med 1:182, 1988.
Diagnostic and therapeutic technology assessment; chelation therapy. JAMA 250:672, 1983.
Dickey LD (ed.): Clinical Ecology. Springfield, Illinois, Charles C. Thomas, 1976.
Donald GF, Hunter GA, Roman W and Taylor AEJ: Current concepts of cutaneous porphyria and its treatment with particular reference to the use of sodium calcium-edetate. Brit J Derm 82:70, 1970.
Donsbach KW: Chelation Therapy; Has the Plug Been Pulled on Our Biggest Killer? Huntington Beach, CA, International Institute of Health, 1981.
Doolan PD, Schwartz SL, Hayes JR, Mullen JC, Cummings NB: An evaluation of the nephrotoxicity of ethylendiaminetetraacetate and diethlenetriaminepentaacetate in the rat. Toxicol Appl Pharmacol 1967;10:481-500.
Dormandy TL: An approach to free radicals. Lancet 1983; ii:1010-14.
Dormandy TL: Free-radical oxidation and antioxidants. Lancet 1978;8:647-50.
Dormany TL: Free-radical reaction in biological systems. Ann R Coll Surg Engl 1980;62:188-94.
Dudley HR, Ritchie AC, Schilling A and Baker WH: Pathologic changes associated with the use of sodium ethylene diamine tetra-acetate in the treatment of hypercalcemia. N Eng J Med 252:331, 1955.
Eaton GJ, Custer P, Crane R: Effects of ultraviolet light on nude mice: Cutaneous carcinogenesis and possible leukomogenesis. Cancer 1978;42:182-88.
EDTA chelation therapy for arteriosclerotic heart disease. Medical Letter 23:51 l981.
EDTA chelation therapy for atherosclerotic cardiovascular disease. Medical Letter 36:48 l994.
EDTA chelation: a rebuttal. J Adv Med 5:3, 1992.
Eliot RS and Blout SG Jr: Calcium, chelates and digitalis. A clinical study. Am Heart J 62:7, 1961.
Ely DL, Mostardi RA, Woebkenberg N, Worstell D: Aerometric and hair trace metal content in learning- disabled children. Environ Res 1981;25(2):325-39.
Emmerson BT: Chronic lead nephropathy. The diagnostic use of calcium EDTA and the association with gout. Aust Ann Med 12:310, 1963.
Ericson JE, Shirahata H, Patterson CC: Skeletal concentrations of lead in ancient Peruvians. N Engl J Med 1979;300:946-51.
Estep HL, Gardner CT Jr, Taylor JP, Minott A and Tucker HStG Jr: Phosphate excretion patterns following intravenous injection of ethylenediaminetetraacetate ((EDTA). J Clin Endocr 25:1385, 1965.
Evers R: Chelation of vascular atheromatous disease. Journal International Academy Metabology 1972;2:51-53.
Favre HR and Wing AJ: Simultaneous 51Cr edetic acid, inulin, and endogenous creatinine clearances in 20 patients with renal disease. Brit Med J 1:84, 1968.
Fedorenko VI: Effect of cysteine, glutathione and 1-p-chlorophenyltetrazole-thione-2 on postradiation changes in the metabolic free radical content of albino rat tissues. Radiobiologiia 1979;19:67-73.
Feigen RD, Shannon DC, Reynolds SL, Shapiro LW and Connelly JP: Lead poisoning in children. Clin Pediat 4:38, 1965.
Feldman EB: EDTA and angina pectoris. Drug Therapy 1975 Mar:62.
Fink CW and Baum J: Treatment of calcinosis universalis with chelating agents. Am J Dis Child 105:390, 1963.
Fischer BH, Marks M, Reich T: Hyperbaric-oxygen treatment of multiple sclerosis. N Engl J Med 1983;308:181-86.
Flamm ES, Demopoulos HB, Seligman ML, Mitamura JA, RansohoffJ: Barbiturates and free radicals, in Popp AJ, Popp RS, Bourke LR, Nelson, Kimelberg HK (eds.): Neural Trauma. New York, Raven Press, 1979, pp 289-300.
Flamm ES, Demopoulos HB, Seligman ML, Poser RG, RansohoffJ: Free radicals in cerebral ischemia. Stroke 1978;9(5):445-47.
Flamm ES, Demopoulos HB, Seligman ML, Tomasula JJ, DeCrescito V, Ransohoff J: Ethanol potentiation of central nervous system trauma. J Neurosurg
Flynn DM: 5-year controlled trial of chelating agents in treatment of thalassaemia major. Arch Dis Child 48:829, 1973.
Foli MR, Hennigan C, Errera J: A comparison of five toxic metals among rural and urban children. Environ Pollut Ser A Ecol Biol 1982;29:261-270.
Foote CS: Chemistry of singlet oxygen VII. Quenching by beta carotene. J Am Chem Soc 1968;90:6233.
Foreman H and Trujillo TT: The metabolism of 14C-labelled ethylene diaminetetraacetic acid in human beings. J Lab Clin Med 43:566, 1954.
Foreman H, Finnegan C and Lushbaugh CC: Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy. JAMA 160:1042, 1956.
Foreman H, Vier M and Magee M: The metabolism of C14 labeled ethylenediaminetetraacetic acid in the rat. J Biol Chem 203:1045, 1953.
Foreman H: Pharmacology of Some Useful Chelating Agents. In Seven MJ and Johnson LA (eds): Metal-Binding in Medicine. Philadelphia, JB Lippincott, 1960.
Foreman H: Summary remarks by the chairman. [Proceedings of a conference on biological apects of metal-binding.] Fed Proc 20 (Suppl 10):257, 1961.
Foreman H: Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis 16:319, 1963.
Foreman H: Use of chelating agents in treatment of metal poisoning with special emphsis on lead). Fed Proc 20 (Suppl 10):191, 1961.
Forssman O and Nordqvist P: The action in vitro and in vivo od sodium versenate on the phagocytic activity of neutrophile leukocytes. Acta Haemat 31:289, 1964.
Fourcans B: Role of phospholipids in transport and enzymic reactions. Adu Lipid Res 1974:147-226.
Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC: Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med 1983;99:450-54.
Fridovich I: Superoxide dismutases. Annu Rev Biochem 1975;147-59.
Friedel W, Schulz FH, Schoder L: Therapy of atherosclerosis through mucopolysaccarides and EDTA (ethylene diamine tetraacetic acid). (German) Deutsch Gesundh 1965;20:1566-70.
Fromke VL, Lee MY and Watson CJ: Porphyrin metabolism during Versenate(r) therapy in lead poisoning. Intoxication from an unusual source. Ann Intern Med 70:1007, 1969.
Frost HB: Coherence treatment of oateoporoses. Orthop Clin North AM 1981;12:649-69.
Frost HM: Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop 1979;143:224-44.
Fuleihan FJD, Kurban AK, Abboud RT, Beidas-jubran N and Farah FS: An objective evaluation of the treatment of systemic scleroderma with disodium EDTA, pyridoxine and reserpine. Brit J Derm 80:184, 1968.
Gaby AR: Nutritional factors in cardiovascular disease. J Holistic Med 1983;5(2):815-828.
Gelderd JB, Welch DW, Fife WP, et al.: Therapeutic effects of hyperbaric oxygen and dimethyl sulfoxide following spinal cord transactions in rats. Undersea Biomedical Research 1980;3:305-20.
Ghiringhelli L and Respighi E: The tubular reabsorption of phosphorus during the test of parathyroid stimulation by versenate (test of Kaiser &Ponsold). Atti Acad Med Lombarda 18:191, 1963.
Ghiringhelli L, Marinoni E and Respighi E: Study of the parathyroid function by means of the Kaiser &Ponsold test in a group of thyroidectomized patients. Minerva Med 54:2829, 1963.
Gibbons HL: Edetate disodium calcium, calcium-channel blockers, and heart disease. JAMA 246:1728, 1981.
Gibson RS, Gage L: Changes in hair arsenic levels in breast and bottle fed infants during the first year of infancy. Sci Total Environ 1982;26:33-40.
Godfrey ME, Agnihotri R, and Strauss A: Chelation and arteriosclerosis. NZ Med J 101(838):21, 1988.
Godfrey ME, Frackleton JP and Chappell LT: Chelation therapy for intermittent claudication (Letter). Z Med J 107:495, 1994.
Godfrey ME: EDTA chelation as a treatment of arteriosclerosis NZ Med J 93:199, 1990.
Goldsmith RE, King LR, Zalme E and Bahr GK: Serum calcium homeostasis in radioiodine treated thyrotoxic subjects as measured by ethylenediamine tetraacetate infusion. Acta Endocrin 58:565, 1968.
Gordon GB and Vance RB: EDTA chelation therapy for atherosclerosis: history and mechanisms of action. Osteopath Ann 4:38, 1976.
Gordon GB, Vance RB: EDTA chelation therapy for atherosclerosis: History and mechanisms of action. Osteopathic Annals 1976;4:38-62.
Gordon T, Kannel WB, Hjortland MC, McNamara PM: Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978;89:157-61.
Gori GB: Observed no-effect thresholds and the definition of less hazardous cigarettes. Journal of Environmental Pathology and Toxicology 1980;3:193-203.
Gotto AM Jr: Chelation therapy in 1984. Texas Medicine 80:36, 1984.
Gould RG: Metals and chelating agents in relation to atherosclerosis. Fed Proc 20 (Suppl 10):252, 1961.
Grier MT and Meyers DG: So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27:1504, 1993.
Grumbles LA: Radionuclide studies of cerebral and cardiac circulation before and after chelation therapy. Read before the American Academy of Medical Preventics, Chicago, Illinois, May 27, 1979. (Transcript available from AAMP, 6151 West Century Blvd., # 1114, Los Angeles, CA 90045.)
Guldager B, Jelnes R, Jorgenson SJ, et al: EDTA treatment of intermittent claudication - a double-blind placebo-controlled study. J Intern Med 231:261, 1992.
Gutteridge JMC, Rowley DA, Halliwell B, Westermarck T: Increased non-protein-bound iron and decreased protection against superoxide-radical damage in cerbrospinal fluid from patients with neuronal ceroid lipfuscinoses. Lancet 1982;ii:459-60.
Gutteridge JMC, Rowley DA, Halliwell B: Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Biochem J 1982;206:605-9.
Gutteridge JMC: Fate of oxygen free radicals in extracellular fluid. Biochem Soc Trans 1982; 10:72-74.
Gutteridge JMC: Ferrous-salt promoted damage to deoxyribose and benzoate, the increased effectiveness of hydroxyl-radical scavengers in the presence of EDTA. Biochem J 243:709, 19987.
Hösli P: Therapy of scleroderma with the disodium salt of ethylenediaminetetraacetic acid; a contribution to the toxicology of versenate. Part I. Arzneimittelforschung 10:65, 1960.
Hösli P: Therapy of scleroderma with the disodium salt of ethylenediaminetetraacetic acid; a contribution to the toxicology of versenate. Part II. Arzneimittelforschung 10:177, 1960.
Halbach KH, Wassman H, Hoheluchter KL, et al.: Clinical course of spinal lesions treated with hyperbaric oxygen. Acta Neurochir 1975;31:297-98.
Halstead BW: The Scientific Basis of EDTA Chelation Therapy. Colton, CA, 1979. Golden Quill Publishers, Box 1278, Colton, CA 92324, 1979.
Hancke C and Flytlie K: Benefits of EDTA chelation therapy on arteriosclerosis. J Adv Med 6:161, 1993.
Hancke C and Flytlie K: Manipulation with EDTA. Ugeskr Laeger 154:2213, 1992.
Hansen JC, Christensen LB, Tarp U: Hair lead concentration in children with minimal cerebral dysfunction. Danish Med Bull 1980;27:259-62.
Hansotia P, Peters H, Bennett M and Brown R: Chelation therapy in Wegener's granulomatosis. Treatment with EDTA. Ann Otol 78:388, 1969.
Hardy HL: Clinical experience with the use of calcium disodium ethylenediaminetetraacetate in the therapy of lead poisoning. Fed Proc 20 (Suppl 10):252, 1961.
Harman D: The aging process. Proc Natl Acad Sci USA 1981;78:7124-28.
Harmon D: The free radical theory of aging. Read before the Orthomolecular Medical Society, San Francisco, California, May 8, 1983. (Available on audio cassette from AUDIO-STATS, 3221 Carter Avenue, Marina Del Rey, CA 90291.)
Harper JW and Gordon GF: Reprints of medical literature on chelation therapy. Los Angeles, American Academy of Medical Preventics, 1975.
Harrison W, Yuracheck J, Benson C: The determination of trace elements in human hair by atomic absorption spectroscopy. Clin Chim Acta 1969;23(l):83-91.
Hatano S, Nishi Y, Usui T: Copper levels in plasma and erythrocytes in healthy Japanese children and adults. Am J Clin Nutr 1982;35:120-26.
Haumont S and Vincent J: Action of calcium versenate on lead fixed in vivo in compact bone. Exp Cell Res 18:404, 1959.
Hausmann E: Changes in plasma phosphate concentration on infusion of calcium gluconate or Na2EDTA. Proc Soc Exp Biol Med 134:182, 1970.
Hay DR: Chelation therapy. N Z Med J 101(841):122, 1988.
Hay DR: Chelation therapy. N Z Med J 101(845):246, 1988.
Heath DA, Knapp MS and Walker WHC: Comparison between inulin and 51Cr-labelled edetic acid for the measurement of glomerular filtration-rate. Lancet 2:1110, 1968.
Heller J and Vostal J: Renal excretion of calcium-disodium-ethylenediamine-tetraacetic acid - a new tubular secretory mechanism? Experientia 20:99, 1964.
Hemmings WA, Williams EW: Transport of large breakdown products of dietary protein through the gut wall. Gut 1978;19:715-23.
Herd JK and Vaughan JH: Calcinosis universalis complicating dermatomyositis - its treatment with Na2EDTA. Report of two cases in children. Arthritis Rheum 7:259, 1964.
Hess ML, Manson NH, Okabe E: Involvement of free radicals in the pathophysiology of ischemic heart disease. Can J Physiol Pharmacol 1982;60(11):1382-89.
Heys AD, Dormandy TL: Lipid peroxidation in iron-overloaded spleens. Clinical Science 1981;60:295-301.
Higgins AC, Pearlstein MS, Mullen JB, et al.: Effects of hyperbaric oxygen therapy on long-tract neuronal conduction in the acute phase of spinal cord injury. J Neurosurg 1981;55(4);501-10.
Hjortland MC, McNamara PM, Kennel WB: Some atherogenic concomitants of menopause: The Framingham Study. Am J Emidemiol 1976;103:304-11.
Holbach KH, Wassman H., Links D: The use of hyperbaric oxygenation in the treatment of spinal cord lesions. Eur Neurol 1977;16:213-21.
Holland JF, Danielson E and Sahagian-Edwards A: Use of EDTA in hypercalcemic patients. Proc Soc Exp Biol Med 84:359, 1953.
Huel G, Boudene C, Ibrahim MA: Cadmium and lead content of maternal and newborn hair: Relationship to parity, birth weight, and hypertension. Arch Environ Health 1981;35(5):221-27.
Hurry VJ, Gibson RS: The zinc, copper, and manganese status of children with malabsorption sydromes and inborn errors of metabolism. Biol Trace Element Res 1982;4:157-73.
Hyperbaric Oxygen Therapy: A Committee Report, February 1981. Undersea Medical Society, Inc., 9650 Rockville Pike, Bethesda, MD 20014 (UMS Publication Number 30 CR(HBO) 2-23-81).
Important Facts You Should Know About the American Board of Chelation Therapy, 1983. American Board of Chelation Therapy, 1312 N.W. Twelfth Street, Moore, Oklahoma 73170.
Ito T, Allen N, Yashon D: A mitochondrial lesion in experimental spinal cord trauma. J Neurosurg 1978;48:434-42.
Iwata K, Yamamota Y: Glycoprotein toxins produced by Candida albicans. Reprinted from Proceedings of the Fourth International Conference on the Mycoses. PAHO Scientific Publication 1977;356:246-57.
Iwata K: Fungal toxins as a parasitic factor responsible for the establishment of fungal infections. Mycopathologia 65:141-54.
Iwata K: Toxins produced by Candida Albicans. Contr Microbiology Immunol 1977;4:77-85.
Jenkins DW: Toxic Trace Metals in Mammalian Hair and Nails. US Environmental Protection Agency publication No. (EPA)-600/4-79049. Environmental Monitoring Systems Laboratory, 1979. (Available from National Technical Information Service, U.S. Department of Commerce, Springfield, VA 2216 1.)
Jesus-Greenberg DA: Acute spinal cord injury and hyperbaric oxygen therapy: A new adjunct in management. Journal of Neurosurgical Nursing 1980;12:155-60.
Jick S and Karsh R: The effect of calcium chelation on cardiac arrhythmias and conduction disturbances. Am J Cardiol 4:287, 1959.
Johnson SAM: Use of the chelating agent edathamil disodium in acrosclerosis, sarcoidosis and other skin conditions with comments on tryptophan metabolism in sarcoidosis. Wisconson Med J 59:651, 1960.
Jonas WB: Effectiveness of EDTA chelation therapy. Circulation 5:1352, 1995.
Jonas WB: Meta-analysis of EDTA chelation: math that doesn't matter. J Adv Med 7:109, 1994.
Jones KH and Fourman P: Edetic-acid test of parathyroid insufficiency. Lancet 2:119, 1963.
Jones RF, Unsworth IP, Marasszeky JE: Hyperbaric oxygen and acute spinal cord injuries in humans. Med J Aust 1978;2:573-75.
Jones RJ: Chelation therapy (Letter). JAMA 250:672, 1983.
Julian JJ: Pass or Bypass? Chelation Extends Life. Hollywood, Wellness Press, 1981.
Kalliomaki JL, Markkanen TK and Mustonen VA: Serum calcium and phosphorous homeostasis in man studied by means of the sodium EDTA test. Acta Med Scan 170:211, 1961.
Kaman RL, Rudolph CJ, McDonagh EW and Walker FM: Effect of EDTA chelation therapy on aortic calcium in rabbits on atherogenic diets; quantitative and histochemical studies. J Adv Med 3:13, 1990.
Kebe SR: ACTH and a chelating agent for schizophrenia. West Med 4:46, 1963.
Kelly DL, Jr., Lassiter KRL, Vongsvivut A, et al.: Effects of hyperbaric oxygen and tissue oxygen studies in experimental paraplegia. J Neurosurg 1972;36:425-29.'
Kennel WB, Hjortland MC, McNamara PM, Gordon T: Menopause and the risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976;85:447-52.
Kitchell JR, Meltzer LE, Seven MJ: Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis 1961;3:338-49.
Kitchell JR, Palmon F, Aytan N, Meltzer LE: The treatment of coronary artery disease with disodium EDTA, a reappraisal. Am J Cardiol 1963;11:501-6.
Kjeldsen K, Astrup P, Wanstrup J: Reversal of rabbit atherosclerosis by hyperoxia. J Atheros Res 1969;10:173.
Klein R and Harris SB: Treatment of scleroderma, sclerodactylia and calcinosis by chelation (EDTA). Am J Med 19:798, 1955.
Klevay L: Hair as a biopsy material-assessment of copper nutriture. Am J Clin Nutr 1970;23(8):1194-202.
Kneller LA, Uhl HSM and Brem J: Successful calcium disodium ethylene diamine tetraacetate treatment of lead poisoning in an infant. N Engl J Med 252:338, 1955.
Koen A, McCann DS and Boyle AJ: Some in vivo effects of chelation. II. Animal experimentation. J Chron Dis 16:329, 1963.
Konradi MG: Use of disodium ethylenediaminetetraacetate test for diagnosing latnet forms of hypoparathyroidism. Prob Endokrinol 23:46, 1977.
Kotin P, Falk HL: Organic peroxides, hydrogen peroxide, epoxides and neoplasia. Radiat Res 1963;3(suppl):193-21 1.
Kozlov VA and Novikova VM: Calcium ion-dependent immunosuppressive effect of ethylenediaminetetraacetic acid (EDTA). Epidemiol Immunobiol 1:69, 1978.
Kurliandchikov VN: Treatment of patients with coronary arteriosclerosis with unithiol in combination with vitamins. (Russian, Kiev) Vrach Delo 1973;6:8.
Laha RK, Dujovny M, Barrionuevo PJ, et al.: Protective effects of methyl prednisolone and dimethyl sulfoxide in experimental middle cerebral artery embolectomy. J Neurosurg 1978;49:508-16.
Lamar CP: Calcium chelation of atherosclerosis, nine years' clinical experience. Read before the Fourteenth Annual Meeting of the American College of Angiology, San Juan, PR, Dec 8, 1968. (transcript available AAMP, 6151 West Century Blvd., * 1114, Los Angeles, CA 90045).
Lamar CP: Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatr Soc 1966;14:272-93.
Lamar CP: Chelation endarterectomy for occlusive atherosclerosis. J Am Geriatrics Soc 15: 272, 1966.
Lamar CP: Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology 15:379, 1964.
Lamar CP: Chelation therapy of occlusive arteriosclerosis in diabetic patients. Angiology 1964;15:379-94.
Lamb DJ and Leake DS: The effect of EDTA on the oxidation of low density lipoprotein. Atherosclerosis 94:35, 1992.
Lambert C, Willis ED: The effect of dietary lipids on 3, 4, benzo(a)pyrene metabolism in the hepatic endoplasmic reticulum. Biochem Pharmcol 1977b;26:1423-77.
Lambert L, Willis ED: The effect of dietary lipid peroxides, sterols and oxidised sterols on cytochrome P450 and oxidative demethylation. Biochem Pharmacol 1977a;26:1417-21.
Leipzig LJ, Boyle AJ, McCann DS: Case histories of rheumatoid arthritis treated with sodium or magnesium EDTA. J Chronic Dis 1970;22:553-63.
Leitner SA: Last chance to live. Wade Allen Publishing, Chesterfield, MO, 1980.
Lelievre P and Betz EH: Effect of versene on oxygen consumption of tissues in vitro. C R Soc Biol 155:199, 1961.
Levine SA: Reinhardt JH: Biochemical-pathology initiated by free radicals, oxidant chemicals, and therapeutic drugs in the etiology of chemical hypersensitivity disease. Journal of Orthmolecular Psychiatry 1983;12(3):166-83.
Liberman UA, Barzel U, De Vries A and Ellis H: Myositis ossificans traumatica with unusual course. Effect of EDTA on calcium, phosphorus and mangenese excretion. Am J Med Sci 254:35, 1967.
Lochte HL Jr, Ferrebee JW and Thomas ED: The effect of heparin and EDTA on DNA synthesis by marrow in vitro. J Lab Clin Med 55435, 1960.
Lockefeer JH, Hackeng WHL and Birkenhagër JC: Parathyroid hormone secretion in disorders of calcium metabolism studied by means of EDTA. Act Endocr 75:286, 1974.
Lonsdale D: EDTA chelation therapy (Letter). Am J Surg 166:316, 1993.
Luchi RJ, Helwig J Jr and Conn HL Jr: Quinidine txoicity and its treatment. An experimental study. Am Heart J 65:340, 1963.
Lyons RD: Chelation: miracle cure or false hope? Med J Aust 142: 519, 1985.
Magee HR: Chelation therapy for atherosclerosis (Letter). Med J Aust 143:127, 1985.
Maisin JR, Decleve A, Gerber GB, Mattelin G, Lambiet-Collier M: Chemical protection against the long-term effects of a single whole-body exposure of mice to ionizing radiation. H. Causes of death. Radiat Res 1978;74:415-35.
Malinovska V, Zechmeister A, Brucknerova E et al: Ultrahistochemical study of the effect of glucagon and Chelation III on arterial wall structure after experimental calcification. Folia Morphologica 28:20, 1978.
Marcelle R and Lecomte J: On the cardiovascular activities of the sodium salt of ethylenediaminetetraacetic acid. C R Soc Biol 153:1483, 1959.
March J: Advanced Organic Chemistry Reactions, Mechanics, and Structure, ad 2. New York, McGraw-Hill, 1978,620.
Margolis S: Chelation therapy is ineffective for the treatment of peripheral vascular disease. Alternative Therapies Health Med 1:53, 1995.
Marlow CG and Sheppard G: [51Cr] EDTA, [hydroxymethyl-14C] inulin-T for the determination of glomerular filtration rate. Clin Chim Acta 28:479, 1970.
Marlowe M, Errera J, Stellern J, Beck D: Lead and mercury levels in emotionally disturbed children. J Orthomol Psychiatr 1983;12(4):260-67.
Marlowe M, Folio R, Hall D, Errera J: Increased lead burdens and trace mineral status in mentally retarded children. J Spec Educ 1982;16:87-99.
Marney SR Jr and Des Prez RM: Rabbit platelet injury by soluble antigen and antibody. III. Effects of the sodium and magnesium salts of EDTA and EGTA. J Immun 106:1446, 1971.
Marsh L and Fraser FC: Chelating agents and teratogenesis. (Letter) Lancet 1:846, 1973.
Masterson WL, Slowinski E: In Chemical Principles. Philadelphia, Saunders, 1977, p. 203, plate 5.
Maxwell GM, Elliot RB and Robertson E: The effect of Na3EDTA-induced hypocalcemia upon the general and coronary hemodynamics of the intact animal. Am Heart J 66:82, 1963.
Mayan H, Salomon O, Pauzner R, et al: EDTA-induced pseudothrombocytopenia. South Med J 85:213, 1992.
Mayes PA: Biologic oxidation, in Martin DW, Mayes PA, Rodwell VW (eds): Harper's Review of Biochemistry. Los Alton, California, Lange Medical Publications, 1983, 129-30.
Mayron LW: Portals of entry-a review. Ann Allerg 1978;40:399-405.
McCann DS, Koen Z, Zdybek G and Boyle AJ: Effect of chelation on phosphorus metabolism in experimental atherosclerosis. Circ Res 11:880, 1962.
McCoy JE, Carre IJ and Freeman M: A controlled trial of edathamil calcium disodium in acrodynia. Pediatrics 25:304, 1960.
McCullach KG: Revised concepts of atherogenesis. Cleve Clin Q 1976;43:247.
McDonagh E, Rudolph, CJ, and Cheraskin E: An oculocerebrovasculometric analysis of the improvement in arterial stenosis following EDTA chelation therapy. J Holistic Med 4:21, 1982.
McDonagh EW and Rudolph CJ: A Collection of Published Papers Showing the Efficacy of EDTA Chelation Therapy. Gladstone, MD, McDonagh Medical Center, 1991.
McDonagh EW, Rudolph CJ, and Cheraskin E: Effect of EDTA chelation therapy plus multivitamin trace mineral supplementation upon vascular dynamics: ankle/brachial doppler systolic blood pressure ratio. J Holistic Med 7:16, 1985
McDonagh EW, Rudolph CJ, and Cheraskin E: The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: a study in serum creatinine. J Holistic Med 4:146, 1982.
McDonagh EW, Rudolph CJ, and Cheraskin E: The effect of intra-venous disodium ethylenediaminetetraacetic acid (EDTA) plus supportive multivitamin/trace mineral supplementation upon fasting serum calcium. Med Hypotheses 11:431, 1982.
McDonagh EW, Rudolph CJ, and Cheraskin E: The glycohemoglobin (HbA1c) distribution in EDTA-chelation-eligible patients. J Orthomolecular Psych 12:72, 1983.
McDonagh EW, Rudolph CJ, and Cheraskin E: The homeostatic effect of EDTA with supportive multivitamin trace mineral supplementation upon high-density lipoproteins (HDL). J Osteopath Phys Surg Calf 8: #2, Spring 1982.
McDonagh EW, Rudolph CJ, and Cheraskin E: The influence of EDTA salts plus multivitamin-trace mineral therapy upon total serum cholesterol/high-density lipoprotein cholesterol. Med Hypotheses 9:643, 1982.
McDonagh EW, Rudolph CJ, Cheraskin E: An oculocerebrovasculometric analysis of the improvement in arterial stenosis following EDTA chelation therapy. J Holistic Med 1982;4(l):21-23.
McDonagh EW, Rudolph CJ, Cheraskin E: The effect of EDTA chelation therapy plus supportive multivitamin-trace mineral supplementation upon renal function: A study in serum creatinine. J Holistic Med 1982;4:146-151.
McDonagh EW, Rudolph CJ, Cheraskin E: The effect of intravenous disodium ethylenediaminetetraacetic acid (EDTA) upon blood cholesterol in a private practice environment. Journal of the International Academy of Preventive Medicine 1982;7:5-12.
McDonagh EW, Rudolph CJ, Cheraskin E: The influence of EDTA salts plus multivitamin-trace mineral therapy upon total serum cholesterol/high-desntiy lipoprotein cholesterol. Medical Hypothesis 1982;9:643-46.
McDonagh EW: Chelation Can Cure: How to Reverse Heart Disease, Diabetes, Stroke, High Blood Pressure or Surgery. Kansas City, Platinum Pen Publications, 1983.
McGill WF: The effects of EDTA chelation therapy on plaque calcium and mineral metabolism in atherosclerotic rabbits. Dissertation Abstracts International Vol. 41, No. 04, October 1980.
McGillen M J and Mancini GBJ: Inefficacy of EDTA chelation therapy for coronary atherosclerosis. N Engl J Med 318:1618, 1988.
McGinnes JE, Proctor PH, DemopouIos HB, Hokanson JA, Van NT: In vivo evidence for superoxide and peroxides production by adriamycin and cis-platium, Autor A (ed.) Active Oxygen and Medicine. New York, Raven Press, 1980.
Medeiros DM, Borgman RF: Blood pressure in young adults as associated with dietary habits, body conformation, and hair element concentrations. Nutr Res 1982;2:455-66.
Medeiros DM, Pellum LK, Brown BJ: The association of selected hair minerals and anthropometric factors with blood pressure in a normosensitive adult population. Nutr Research 1983;3:51-60.
Mehbod H: Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA 201:972, 1967.
Meltzer LE, Kitchell JR, and Palmon FJ: The long term use, side effects, and toxicity of disodium ethylenediamine tetraacetic acid (EDTA). Am J Med Sci 242:11, 1961.
Meltzer LE, Palmon FJ, and Kitchell JR: Hypoglycemia induced by disodium ethylenediamine tetraacetic acid. Lancet 2:637, 1961.
Meltzer LE, Ural ME, Kitchell JR: The treatment of coronary artery disease with disodium EDTA, in Seven MJ, Johnson LA (eds.): Metal Binding in Medicine. Philadelphia, J.B. Lippincott Co., 1960, pp 132-36.
Meltzer LE: Chelation Therapy. In Seven MJ and Johnson LA (eds): Metalbinding in Medicine. Philadelphia, JB Lippincott, 1960.
Meyer MS, Chalmers TM, Reynolds JJ: Inhibitory effect of follicular stimulating hormone in parathormone in rat calvaria in vitro. Read before the Frances and Anthony DAnna International Memorial Symposium, Clinical Disorders of Bone and Mineral Metabolism, May 8, 1983. (Abstract available from Henry Ford Hospital, Dearborn, Michigan.)
Mischol HR and Wildbolz R: Instrumental chemolysis of renal calculi: Indications and dangers. J Urol 105:607, 1971.
Müller SA, Brunstig LA and Winkelmann RK: The treatment of scleroderma with the new chelating agent edathamil. Arch Dermatol 3:305, 1962.
Moel DI, Kuman K: Reversible nephrotoxic reactions to a combined 2, 3-dimercapto-l-propanol and calcium disodium ethylnediaminetetraacetic acid regimen in asymptomatic children with elevated blood levels. Pediatrics 1982;70(2):259-62.
Moncrieff AA, Koumides OP, Clayton BE, Patrick AD, Renwick AGC and Roberts GE: Lead poisoning in children. Arch Dis Child 39:1, 1964.
Mongan ES: The treatment of progressive systemic sclerosis with disodium edetate. Arthitis Rheum 8:1145, 1965.
Montgomery MR: Advances in medical fraud: chelation therapy replaces Laetrile. J Florida Med Assoc 73:681, 1986.
Morel DW, Hessler JR, Chisolm GM: Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. Journal of Lipid Research 1983;24:1070-76.
Morgan JM: Chelation therapy in lead nephropathy. South Med J 68:1001, 1973.
Moser PB, Krebs NK, Blyler E: Zinc hair concentrations and estimated zinc intakes of functionally delayed normal sized and small-for-age children. Nutr Research 1982;2:585-90.
Muller SA, Brunsting LA, Winkelmann RK: Treatment of scleroderma with a new chelating agent, edathamil. Arch Dermatol 1959;80:101.
Musa-Alzubaida L, Lombeck 1, Kasperek K, Feinendegen LE, Bremer HJ: Hair selernium content during infancy and childhood. Eur J Pediatr 1982;139:295-96.
Myers HL: Topical chelation therapy for varicose pigmentation. Angiology 17:66, 1966.
Nakano J, Cole B and Ishii T: Effects of disodium EDTA on the cardiovascular responses to prostaglandin E1. Experientia 24:808, 1968.
Nayler WG: Ventricular arrhythmias following the administration of Na2EDTA. J Pharmacol Exp Ther 137:5, 1962.
Nedergaard OA and Vagne A: Effect of EDTA and other chelating agents on norepinephrine uptake by rabbit aorta in vitro. Proc West Pharmacol Soc 11:87, 1968.
Neldner KH, Winklemann RK and Perry HO: Scleroderma. An evaluation of treatment with disodium edetate. Arch Derm 86:305, 1962.
Nguyen-The-Minh: Treatment of digitalis intoxication with EDTA Na2. Presse Med 71:2385, 1963.
Nikitina EK and Abramova MA: Treatment of atherosclerosis with Trilone B (EDTA). Kardiologiia 12:137, 1972.
Nodine JH: Edetic acid therapy. (Letter) JAMA 212:628, 1970.
Nolan KR: Copper toxicity syndrome. J Orthomol Psychiatr 1983; 12(4):270-82.
Offer GW: The antagonistic action of magnesium ions and ethylenediaminetetraacetate on myosin A ATPase (potassium activated). Biochim Biophys Acta 89:566, 1964.
Oliver LD, Mehta R and Saries HE: Acute renal failure following administration of ethylenediamine-tetraacetic acid (EDTA). Tex Med 80:40, 1984.
Olszewer E and Carter JP: EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 27(1):41, 1988.
Olszewer E and Carter JP: EDTA Chelation therapy: a retrospective study of 2,870 patients. J Adv Med 27:197, 1989.
Olszewer E, Sabbag FC, and Carter JO: A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 82:173, 1990.
Olwin JH, Koppel JL: Reduction of elevated plasma lipid levels in atherosclerosis following EDTA chelation therapy. Proc Soc Exp Biol Med 1968;128:1137-39.
Olwin JH: EDTA Chelation Therapy. Read before the American Holistic Medical Association, University of Wisconsin, La Crosse, Wisconsin, May 28, 1981. (Available on audio cassette, AHMI, 6932 Little River Turnpike, Annandale, Virginia 22003.)
Ontka JA: Physical and chemical changes in isolated chylomicrons: prevention by EDTA. J Lipid Res 11:367, 1970.
Oser BL, Oser M and Spencer HC: Safety evaluation studies of calcium EDTA. Toxicol Appl Pharmacol 5:142, 1963.
Oser BL: Observations on the chronic ingestion of a chelating agent by rats and dogs. Fed Proc 20(Suppl 10):158, 1961.
Painter JT and Morrow EJ: Porphyria. Its manifestations and treatment with chelating agents. Texas State J Med 55:811, 1959.
Panganamala RV, Sharma HM, Sprecher H, Geer JC, Cornwell DG: A suggested role for hydrogen peroxide in the biosynthesis of prostaglandins. Prostaglandins 1974;8:3-11.
Parfitt AM: Study of parathyroid function in man by EDTA. J Clin Endocr 29:569, 1969.
Passwater PA, Cranton EM: Trace Elements, Hair Analysis and Nutrition, New Canaan, Connecticut, Keats Publishing, Inc., 1983.
Patterson R: Chelation therapy and Uncle John. CMAJ 140(7):829, 1989.
Pavek K, Drinal J and Selecky FV: Circulatory effects of disodium edetate in digoxin-induced ventricular tachycardia. Cardiologia 50:297, 1967.
Payne BA and Pierre RV: Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clinic Proc 59:123, 1984.
Payne JM and Sansom BF: The relative toxicity in rats of disodium ethylene diamine tetra-acetate, sodium oxalate and sodium citrate. J Physiol 170:613, 1964.
Peng CF, Kane JJ, Murphy ML and Straub KD: Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by Ca2+-chelating agents. J Mole Cell Cardiol 9:897, 1977.
Peng CF, Kane JJ, Murphy ML, Straub KD: Abnormal mitochondrial oxidative phosphorylation of ischemic I klil it: I I IMES= myocardiurn reversed by calcium chelating agents. J Mot Cel Cardiol 1977;9:897-908.
Pentel P, Jorgensen C, and Somerville J: Chelation therapy for the treatment of atherosclerosis, an appraisal. Minn Med Feb:101, 1984.
Peripheral Flow Opened Up. Medical World News, Mar 15, 1963; 4:36-39.
Perry HM Jr and Schroeder HA: Depression of cholesterol levels in human plasma following ethylenediamine tetraacetate and hydralazine. J Chron Dis 2:520, 1955.
Perry HM Jr and Schroeder HA: Lesions resembling vitamin B complex deficiency and urinary loss of zinc produced by ethylenediamine tetraacetate. Am J Med 22:168, 1957.
Perry HM Jr: Chelation therapy in circulatory and sclerosing diseases. Fed Proc 20 (Suppl 10):254, 1961.
Peters HA, Croft WA, Woolson EA, Darcey BA: Arsenic, chromium, and copper poisoning from burning treated wood. N Engl J Med 1983;308(22):1360-61.
Peters HA, Eichman PL and Reese HH: Therapy of acute, chronic and mixed hepatic porphyria patients with chelating agents. Neurology 8:621, 1958.
Peters HA, Johnson SAM, Cam S, Oral S, Müftü Y and Ergene T: Hexachlorobenzene-induced porphyria: Effect of chelation on the disease, porphyrin and metal metabolism. Am J Med Sci 251:314, 1966.
Peters HA: Chelation therapy in acute, chronic and mixed porphyria, in Seven MJ, Johnson LA (eds.): Metal Binding in Medicine. Philadelphia, J.B. Lippincott Co., 1960, pp 190-99.
Peters HA: Trace minerals, chelating agents and the porphyrias. Fed Proc 1961;20(3) (Part II) (suppl 10):227-34.
Peterson GR: Adverse effects of chelation therapy. (Letter) JAMA 250:2926, 1983.
Petkau A: Radiation protection by superoxide dismutase. Photochem Photobiol 1978;28:765-74.
Peto R, Doll R, Buckley JD, Sporn MB: Can dietary beta-carotene materially reduce human cancer rates? Nature 1981;290:201.
Petrovic L, Stanovic M, Savicevic M and Poleti D: Aerosol inhaltion of CaNa2E.D.T.A. (mosatil) by workers constantly exposed to lead poisoning. Brit J Indust Med 17:201, 1960.
Pietronigro DD, Demopoulos HB, Hoveepian M, Flamm ES: Brain ascorbic acid (AA) depletion during cerebral ischemia. Stroke 1982;13(l):117.
Platts-Mills A: EDTA chelation therapy. NZ Med J, 101(849):465, l988.
Poole CP: Electron Spin Resonance. A Comprehensive Treatise on Experimental Techniques. New York, Interacience Publishers, 1967.
Popovici A, Geschickter CF, Reinovsky A and Rubin M: Experimental control of serum calcium levels in vivo. Proc Soc Exper Biol & Med 74:415, 1950.
Price JM: Some effects of chelating agents on tryptophan metabolism in man. Fed Proc 20 (Suppl 10):223, 1961.
Proceedings: Hearing on EDTA Chelation Therapy of the Ad Hoc Scientific Advisory Panel on Internal Medicine of the Scientific Board of the California Medical Society, March 26, 1976, San Francisco, California. (Transcript available from AAMP, 6151 West Century Blvd., * 1114, Los Angeles, CA 90045).
Protocol for the Safe and Effective Use of EDTA Chelation Therapy, 1983. American Board of Chelation Therapy, 1312 N.W. Twelfth Street, Moore, Oklahoma 73170.
Pryor WA (ed): Free Radicals in Biology. Volumes 1-3. New York, Academic Press, 1976.
Pryor WA: Free radical reactions and their importance in biochemical systems. Fed Proc 1973;32:1862-69.
Pullman TN, Lavender AR and Forland M: Synthetic chelating agents in clinical medicine. Ann Rev Med 14:175, 1963.
Randolph TG: Human Ecology and Susceptibility to the Chemical Environment. Springfield, Illinois, Charles C. Thomas, 1962.
Rathmann KL and Golightly LK: Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 18:1000, 1984.
Raymond JP, Merceron R, Isaac R, Wahbe F: Effects of EDTA and hypercalcemia on plasma prolactin, parathyroid hormone and calcitonin in normal and parathyroidectomized individuals. Read before the Frances and Anthony DAnna International Memorial Symposium, Clinical Disorders of Bone and Mineral Metabolism, May 8, 1983. (Abstract avialable from Henry Ford Hospital, Dearborn, Michigan.)
Raymond JZ and Gross PR: EDTA: preservative dermatitis. Arch Derm 100:436, 1969.
Rees EL: Aluminum poisoning Papua New Guinea natives as shown by hair testing. J Orthomol Psychiatr 1983;12(4):312-13.
Remagen W, Hiller FK and Sanz CM: Metabolic changes in experimental poisoning with ethylenediamine-tetraacetic acid. Arzneimittelforschung 11:1097, 1961.
Renoux M and Mikol C: Chelation. Presse Med 72:3117, 1964.
Reuber MD and Bradley JE: Acute versenate nephrosis occurring as a result of treatment for lead intoxication. JAMA 174:263, 1960.
Reuber MD and Schmieler GC: Edetate kidneys lesions in rats. Arch Environ Health 5:430, 1962.
Reuber MD: Accentuation of Ca edetate nephrosis by cortisone. Arch Path 76:382, 1963.
Reuber MD: Calcium disodium edetate nephrosis in female rats of varying ages. J Path 97:335, 1969.
Reuber MD: Hepatic lesions in young rats given calcium disodium edetate. Toxicol Appl Pharmacol 11:321, 1967.
Reuber MD: Severe nephrosis in older male rats given calcium disodium edetate. Arch Environ Health 15:141, 1967.
Reuter H, Niemeyer G and Gross R: The distribution of EDTA and citrate in blood and plasma. Throm Diath Haemorrh 19:213, 1968.
Rieders F, Dunnington WG and Brieger H: The efficacy of edathamil calcium disodium in the treatment of occupational lead poisoning. Indust Med 24:195, 1955.
Riordan HD, Cheraskin E, Dirks M, et al: EDTA chelation/hypertension study: clinical patterns as judged by the Cornell Medical Index Questionnaire. J Orthomolelcular Med 4:91, 1989.
Riordon HD, Cheraskin E, Dirks M, et al: Another look at renal function and the EDTA treatment process. J Ortho Med 2:185, 1987.
Riordon HD, Cheraskin E, Dirks M, et al: Electrocardiographic changes associated with EDTA chelation therapy. J Adv Med 1:191, 1988.
Robinson DM: Chelation therapy. N Z Med J 74:750, 1982.
Rosen H, Klebanoff SJ: Bactericidal activity of a superoxide anion-generating system. J Exp Med 1979;149:27-39.
Rosenbaum JL, Mason D and Seven MJ: The effect of disodium EDTA on digitalis intoxication. Am J Med Sci 240:77, 1960.
Rossi EC: Effects of ethylenediaminetetraacetic acid (EDTA) and citrate upon platelet glycolysis. J Lab Clin Med 69:204, 1967.
Rotota MC and Sanowski R: Acute intermittent porphyria. J Med Soc New Jersey 61:101, 1964.
Rowe AH, Rowe AH Jr: Food Allergy: Its Manifestations and Control and the Elimination Diets. Springfield, Illinois, Charles C. Thomas, 1972.
Rubin M, Gignac S, Bessman SP and Belknap E: Enhancement of lead excretion in humans with EDTA. Science 117:659, 1953.
Rudolph CJ, McDonagh EW and Barber RK: A non-surgical approach to obstructive carotid stenosis using EDTA chelation. J Adv Med 4:157, 1991.
Rudolph CJ, Samuels RT and McDonagh EW: Visual field evidence of macular degeneration reversal using a combination of EDTA and multiple vitamin and trace mineral therapy. J Adv Med 7:203, 1994.
Rutman JZ, Melttzer LE, Kitchell JR, et al: Effect of metal ions on in vitro gluconeogensis in rat kidney cortex slices. Am J Physiol 208:841, 1965.
Sachs HK, Blanksma LA, Murray EF and O'Connell MJ: Ambulatory treatment of lead poisoning: report of 1,155 cases. Pediatrics 46:389, 1970.
Saltin B, Karlsson J: Muscle Metabolism During Exercise. New York, Plenum Publishing Co., 1971, p 395.
Samuelsson B: Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
Schaefer A, Komlos M, Seregi A: Lipid peroxidation as the cause of the ascorbic acid induced decrease of ATPase activities of rat brain microsomes and its inhibition by biogenic amines and psychotropic drugs. Biochem Pharmacol 1975;24:1781-86.
Schaefer A, Komlos M, Seregi A: Lipid peroxidation as the cause of the ascorbic acid induced increase of ATPase activities of rat brain microsomes and its inhibition by biogenic amines and psychotropic drugs. Biochem Pharmcol 1975;24:1781-86.
Schroder HA: The Poisons Around Us. Bloomington, Indiana, Indiana University Press, 1974, 49.
Schroeder HA, Menhard EM and Perry HM Jr: Antihypertensive effects of metal binding agents. J Lab & Clin Med 23:416, 1955.
Schroeder HA, Perry HM, Jr: Antibypertensive effects of metal binding agents. J Lab Clin Med 1955;46:416.
Schroeder HA: A practical method for the reduction of plasma cholesterol in man. J Chron Dis 4:461, 1956.
Schubert J: Chelation in medicine. Sci Am 214:40, 1966.
Schwartz SL, Hayes JR, Ide RS, et al: Studies of the neohrotoxicity of ethylene diaminetetraacetic acid, Biomed Pharm 15:377, 1966.
Schwartz SL, Johnson CB, and Doolan PD: Study of the mechanism of renal vacuologenesis induced in the rat by ethylenediaminetetraacetate. Mol Pharm 6:54, 1970.
Schwartz SL, Johnson CB, Hayes JR and Doolan PD: Subcellular localization of ethylenediaminetetraacetate in the proximal tubular cell by the rat kidney. Biochem Pharmacol 16:2413, 1967.
Scott PJ. Chelation therapy: evolution or devolution of a nostrum? N Z Med J 101:109, 1988.
Scott PJ: Chelation therapy for degenerative vascular disease. N Z Med J 95:538, 1982.
Sehnert KW, Claque AF, and Cheraskin E: The improvement in renal function following EDTA chelation and multivitamin trace mineral therapy: A study in creatinine clearance. Med Hypotheses 15:301, 1984.
Selander S: Treatment of lead poisoning. A comparison between the effects of sodium calcium edetate and penicillamine administered orally and intravenously. Brit J Indust Med 24:272, 1967.
Seligman ML, Flamm ES, Goldstein BD, Poser RG, Demopoulos HB, RansohoffJ: Spectrofluorescent detection of malonaldehyde as a measure of lipid free radical damage in response to ethanol potentiation of spinal cord trauma. Lipids 1977;12(11):945-50.
Seligman ML, Mitamura JA, Shera N, Demopoulos HB: Corticosteroid (methylprednisolone) modulation of photoperoxidation by ultraviolet light in lipsomes. Photochem Photobiol 1979;29:549-58.
Seto DSY and Freeman JM: Lead nephropathy in childhood. Am J Dis Child 107:337, 1964.
Seven MJ, Johnson LA (eds.): Metal Binding in Medicine: Proceedings of a Symposium Sponsored by Hahnemann Medical College and Hospital, Philadelphia. Philadelphia, J.B. Lippincott Co. 1960.
Seven MJ: Observations on the dosage of intravenous chelating agents. Antibiotic Med 5:251, 1958.
Shibata S: Toxicological studies of EDTA salt (sodium ethylenediamine tetra-acetate. Folia Pharmacol Japonica 52:113, 1956, and Chem Abst 51:9918, 1957.
Shrand H: Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1:310, 1961.
Sies H, Summer KH: Hydroperoxide-metabolizing systems in rat liver. Eur J Biochem 1975;57:503-12.
Sincock A: Life extension in the rotifer by application of chelating agents. J Gerontol 1975;30:289-93.
Singal PK, Kapur N, Dhillon KS, Beamish RE, Dballa NS: Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol 1982;60(11):1340-97.
Skoog DA, West DM: Volumetric methods based on complex-formation reactions, in Fundamentals of analytical chemistry, New York, Holt, Rinehart and Winston, Inc., 1969, 338-60.
Smith LL: Cholesterol Autooxidation. New York, Plenum Press, 1981.
Soffer A, Chenoweth M, Eichhorn G, Rosoff B, Rubin M, Spencer H: Chelation Therapy, Springfield, Illinois, Charles C. Thomas, 1964.
Soffer A, Toribara T, Sayman A: Myocardial responses to chelation. Br Heart J 1961 Nov;23:690.
Soffer A: Chelation therapy for cardiovascular disease, in Soffer A (ed.): Chelation Therapy, Springfield, Illinois, Charles C. Thomas, 1964, pp 15-63.
Speer F (ed.): Allergy of the Nervous System. Springfield, Illinois, Charles C. Thomas, 1970.
Sukoff MH, Hollin SA, Espinosa OE, et al.: The protective effect of hyperbaric oxygenation in experimental cerebral edema. J Neurosur 1968;29:236-39.
Sukoff MH, Ragatz RE: Use of hyperbaric oxygen for acute cerebral edema. Neurosurgery 1982; 10:29-38.
Sukoff MH: Central nervous system: Review and update cerebral edema and spinal cord injuries. HBO Review 1980;1:189-95.
Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1981;1(8233):1293-94. 1~5.
Swank R: A Biochemical Basis of Multiple Sclerosis. Springfield Illinois, Charles C. Thomas, 1961.
Tappel AL: Lipid peroxidation damage to cell components. Fed Proc 1973;32:1870-74.
Tappel AL: Will antioxidant nutrients slow aging processes? Geriatrics 1968;23:97-105.
Taylor CB, Peng SK, Werthessen NT, Tharn P, Lee KT: Spontaneously occurring angiotoxic derivatives of cholesterol. Am J Clin Nutr 1979;32:40.
Thatcher RW, Lester ML, McAlester R, Horst R: Effects of low levels of cadmium and lead on cognitive functioning in children. Arch Environ Health 1982;37(3):159-66.
Thimaya S, Ganapathy SN: Selenium in human hair in relation to age, diet, pathological condition and serum levels. Sci Total Environ 1982;24:41-49.
Truss CO: Restoration of immunologic competence to candide abbicans. Orthomolecular Psychiatry 1980;9(4):287-301.
Truss CO: The Role of candida albicans in human illness. Orthomolecular Psychiatry 1980;9(4):228-38.
Truss CO: Tissue injury induced by candida albicans. Orthomolecular Psychiatry 1978;7(l):17-37.
Vanderhoof JA, et al.: Hair and plasma zinc levels following exclusion of biliopancreatic secretions from functioning gastrointestinal tract in humans. Dig Dis Sci 1983;28(4):300-5.
Vesslinovitch D, Wissler RW, Fischer-Dzoga K, Hughes R, DuBien L: Regression of atherosclerosis in rabbits. I. Treatment with low fat diet, hyperoxia and hypolipidemic agents. Atherosclerosis 1974;19:259.
Vincent GM, Anderson JL, Marshall HW: Coronary spasm producing coronary thrombosis and myocardial infarction. N Engl J Med 1983;309(14):220-39. 157
Vladimirov YA, Sergeer PV, Seifulla RD, Rudnev YN: Effect of steroids on lipid peroxidation and liver mitochondrial membranes: Molekuliarnaia Biologiia (Russian, Moscow) 1973;7:247-62. (Translated by Consultants Bureau, a division of Plenum Publishing Inc., New York.)
Walker F: The effects of EDTA chelation therapy on plaque, calcium, and mineral metabolism in arteriosclerotic rabbits, Ph.D thesis. Texas State University, 1980. (Available from University Microfilm International, Ann Arbor, MI 48016.)
Walker WA, Isselbacher KJ: Uptake and transport of macromolecules by the intestine: Possible role in clinical disorders. Gastroenterology 1974;67:531-50.
Walling C: Forty years of free radicals, in Pryor WA (ad): Organic Free Radicals. Washing, D.C., American Chemical Society, 1978.
Wartman A, Lampe TL, McCann DS, Boyle AJ: Plaque reversal with MgEDTA in experimental atherosclerosis: Elastin and collagen metabolism. J Atheros Res 1967;7:331.
Wedeen RP, Mallik DK, Batuman V: Detection and treatment of occupational lead nephropathy. Arch Intern Med 1979;139:53-57.
Willett WC, Morris JS, Pressel S, et al.: Prediagnostic serum selenium and risk of cancer. Lancet 1983;2(8343):130-34.
Williams DR, Halstead BW: Chelating agents in medicine. J Toxicol: Clin Toxicol 1983:19(10):1081-115.
Wills ED: Lipid peroxide formation in microsomes. Biochem J 1969;113:325-32. 166
Wills ED: Mechanisms of lipid peroxide formation in tissues: Role of metals and haematin proteins in the catalysis of the oxidation of unsaturated fatty acids. Biochim Biophys Acta 1965;98:238-51.
Willson RL: Iron, zinc, free radicals and oxygen tissue disorders and cancer control, in Iron Metabolism, Ciba Foudn Symp 51 (new series). Amsterdam: Elsevier, 1977, 331-54.
Wissler RW: Principles of the pathogenesis of atherosclerosis, in Braunwald E (ed): Heart Disease. Philadelphia, W.B. Saunders Col, 1980, pp 1221-36.
Wissler, RW, Vesselinovitch D: Regression of atherosclerosis in experimental animals and man. Mod Concepts Cardiovasc Dis 1977;46:28.
Yagi K, Ohkawa H, Ohishi N, Yamashita M, Nakashima T: Lesion of aortic intima caused by intravenous administration of linoleic acid hyperoxide. J Appl Biochem 1981;3:58-65.
Yamanaka S, Tanaka H, Nishimura M: Exposure of Japanese dental workers to mercury. Bull Tokyo Den Coll 1982;23:15-24.
Yea JD, Stabback S, McKinsey B: Study of the effects of hyperbaric oxygenation on experimental spinal cord injury. Med J Aust 1977;2:145-147.
Yeo JD, Lawry C: Preliminary report on ten patients with spinal cord injuries treated with hyperbaric oxygenation. Med J A ust 1978;2:572-73.
Yokel RA: Hair as an indicator of excessive aluminum exposure. Clin Chem 1982;28(4)662-65.
Zapadnick VI, at al.: Pharmacological
activity of unithiol and its use in clinical practice. (Russian, Kiev) Vrach
Delo 1973;8:122.